09:42 AM EST - Theratechnologies Inc. : Today announced that the U.S. Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) goal date of January 22, 2024 to the Company’s supplemental Biologics License Application (sBLA) of the F8 formulation of tesamorelin. Theratechnologies Inc.
shares T.TH are trading unchanged at $2.65.
